Supernus Pharmaceuticals Files 8-K for Regulation FD Disclosure
Ticker: SUPN · Form: 8-K · Filed: 2024-10-30T00:00:00.000Z
Sentiment: neutral
Topics: regulation-fd, disclosure
Related Tickers: SUPN
TL;DR
SUPN filed an 8-K for a Reg FD disclosure - could be big news.
AI Summary
On October 30, 2024, Supernus Pharmaceuticals, Inc. filed an 8-K report. The filing indicates that the company is providing a Regulation FD Disclosure. No specific details regarding the nature of the disclosure, such as financial figures or material events, are provided in the excerpt.
Why It Matters
This filing signals that Supernus Pharmaceuticals is making a public disclosure under Regulation FD, which could contain material information relevant to investors.
Risk Assessment
Risk Level: medium — The filing itself is a standard disclosure, but the lack of specific details about the Regulation FD disclosure introduces uncertainty about potential material events.
Key Players & Entities
- Supernus Pharmaceuticals, Inc. (company) — Registrant
- October 30, 2024 (date) — Date of earliest event reported
FAQ
What is the specific nature of the Regulation FD Disclosure made by Supernus Pharmaceuticals?
The provided excerpt does not specify the content of the Regulation FD Disclosure; it only states that one was made on October 30, 2024.
What is Supernus Pharmaceuticals' principal executive office address?
The principal executive offices are located at 9715 Key West Ave, Rockville, MD 20850.
What is Supernus Pharmaceuticals' telephone number?
The company's telephone number is (301) 838-2500.
Under which section of the Securities Exchange Act is this 8-K filed?
This 8-K is filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
What is the state of incorporation for Supernus Pharmaceuticals?
Supernus Pharmaceuticals, Inc. is incorporated in Delaware.
Filing Stats: 533 words · 2 min read · ~2 pages · Grade level 10.7 · Accepted 2024-10-30 16:38:08
Key Financial Figures
- $0.001 — ange on which registered Common Stock, $0.001 par value per share SUPN The Nasdaq Sto
Filing Documents
- supn-20241030.htm (8-K) — 25KB
- 0001356576-24-000062.txt ( ) — 145KB
- supn-20241030.xsd (EX-101.SCH) — 2KB
- supn-20241030_lab.xml (EX-101.LAB) — 21KB
- supn-20241030_pre.xml (EX-101.PRE) — 12KB
- supn-20241030_htm.xml (XML) — 3KB
01 Regulation FD
Item 7.01 Regulation FD Supernus Pharmaceuticals, Inc. ("Supernus" or the "Company") today released new data from its exploratory open-label Phase 2a clinical study of SPN-820 in adults with major depressive disorder. The Company announced that among the study's participants SPN-820 demonstrated a rapid Montgomery sberg Depression Rating Scale (MADRS) response rate (corresponding with a greater than 50% reduction) of 50.0% and a remission rate (corresponding with a MADRS of no greater than 10), of 35.0%, in each case at four hours, with additional improvement to 84.2% and 63.2%, respectively, by Day 10. The information in this Item 7.01 is being "furnished" and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, whether made before or after the date of this report, except as shall be expressly set forth by specific reference in such filing. 2
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SUPERNUS PHARMACEUTICALS, INC. DATED: October 30, 2024 By: /s/ Timothy C. Dec Timothy C. Dec Senior Vice President and Chief Financial Officer 3